title: Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
abstract: The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma. The genotype of the tumors was assessed with fluorescent in situ hybridization with locus specific probes for the region 1p36. Four of the 24 patients responded (17%). Fifty percent of patients were still free from progression at 6 months and 21% were free from progression at 12 months. Although a clear relation existed between loss of 1p and response to temozolomide chemotherapy, this relation was absent in salvage PCV chemotherapy.
authors.affiliation: Department of Neuro-Oncology, Erasmus MC, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
authors.forename: V H J M
authors.initials: VH
authors.lastname: Triebels
authors.forename: M J B
authors.initials: MJ
authors.lastname: Taphoorn
authors.forename: A A
authors.initials: AA
authors.lastname: Brandes
authors.forename: J
authors.initials: J
authors.lastname: Menten
authors.forename: M
authors.initials: M
authors.lastname: Frenay
authors.forename: A
authors.initials: A
authors.lastname: Tosoni
authors.forename: J M
authors.initials: JM
authors.lastname: Kros
authors.forename: E Biemond-ter
authors.initials: EB
authors.lastname: Stege
authors.forename: R H
authors.initials: RH
authors.lastname: Enting
authors.forename: A
authors.initials: A
authors.lastname: Allgeier
authors.forename: I
authors.initials: I
authors.lastname: van Heuvel
authors.forename: M J
authors.initials: MJ
authors.lastname: van den Bent
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy / Q000235:genetics; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics / Q000648:ultrastructure; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics / Q000648:ultrastructure; D015331:Cohort Studies; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000235:genetics; D011344:Procarbazine / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D017384:Sequence Deletion; D000077204:Temozolomide; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018906:Antineoplastic Agents, Alkylating; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine; D003606:Dacarbazine; D000077204:Temozolomide